RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18

Benzinga Newsdesk www.benzinga.com Positive 73.5%

Neg 0% Neu 0% Pos 73.5%

RBC Capital analyst Luca Issi initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces Price Target of $18.